Replies to post #1110 on Galectin Therapeutics Inc. (GALT)

[Darwinian]

I got hung up on the turn of the century phrase too. But I appreciate IRA hopeful's history lesson. It's helpful to know, and some of this stuff is tough to find anymore.

I often write replies to this board quickly when I'm at work and I probably didn't explain myself too well. I noticed today that LJPC's news ticker listed pre-clinical efficacy of their "oral" formulation against NASH (pasted below):

8:02 am La Jolla Pharmaceutical announces positive pre-clinical data for oral galectin-3 inhibitor in nonalcoholic steatohepatitis (LJPC) : Co announced positive pre-clinical data for LJPC-1010 in non-alcoholic steatohepatitis. LJPC-1010 is a derivative of GCS-100, a carbohydrate inhibitor of galectin-3, which has shown activity in chronic kidney disease in a Phase 2 trial.---

In a pre-clinical study of liver fibrosis in the STAM model of NASH, LJPC-1010 showed a significant reduction (p
In addition to NAFLD, animals in the LJPC-1010 group had decreased yellowing of the liver, decreased liver weight and decreased fibrosis compared to the control group.
Like GCS-100, LJPC-1010 is a modified pectin, however, LJPC-1010, at 50 mg/kg showed significant activity in NASH compared to GCS-100 at 300 mg/kg which showed a trend toward improvement but did reach statistical significance.
LJPC-1010 given orally was comparable to an equivalent dose of GCS-100 given intravenously.

I guess there are a number of factors that will influence which horse(s) will eventually win this race. I would hope that best efficacy would prevail. I've been less concerned about LJPC since learning of their drugs derivation. I have been watching Genfit's candidate for NASH and it looks like they have a pretty good contender, though information about it doesn't seem as readily available. My current understanding is that they are targeting earlier stages of the disease but that they do feel that it will also work to reverse fibrosis. Time will tell. I think they are in phase 2 with results expected towards end of year. Have any of you deep digging investors looked into Genfit?
Thanks,

—D